Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PTGX 
Protagonist Therapeutics Inc (PTGX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PTGX (5-star) is a WEAK-BUY. BUY since 16 days. Profits (-21.55%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 166.02% | Avg. Invested days 60 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.00B USD | Price to earnings Ratio 11.43 | 1Y Target Price 69.1 |
Price to earnings Ratio 11.43 | 1Y Target Price 69.1 | ||
Volume (30-day avg) 1425112 | Beta 2.33 | 52 Weeks Range 24.22 - 60.60 | Updated Date 04/1/2025 |
52 Weeks Range 24.22 - 60.60 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 63.34% | Operating Margin (TTM) 74.3% |
Management Effectiveness
Return on Assets (TTM) 28.66% | Return on Equity (TTM) 54.39% |
Valuation
Trailing PE 11.43 | Forward PE 26.39 | Enterprise Value 2560497216 | Price to Sales(TTM) 6.91 |
Enterprise Value 2560497216 | Price to Sales(TTM) 6.91 | ||
Enterprise Value to Revenue 5.89 | Enterprise Value to EBITDA 10.01 | Shares Outstanding 61384300 | Shares Floating 49266417 |
Shares Outstanding 61384300 | Shares Floating 49266417 | ||
Percent Insiders 1.38 | Percent Institutions 105.28 |
Analyst Ratings
Rating 4.4 | Target Price 57.5 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Protagonist Therapeutics Inc
Company Overview
History and Background
Protagonist Therapeutics, Inc. is a biopharmaceutical company founded in 2006 and based in San Diego, California. It focuses on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Key milestones include the clinical development of rusfertide and other peptide therapeutics.
Core Business Areas
- Drug Development: Research and development of peptide-based therapeutics for various diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships: Collaborating with other pharmaceutical companies for drug development and commercialization.
Leadership and Structure
The leadership team includes Dinesh V. Patel, Ph.D., President and Chief Executive Officer. The organizational structure involves departments for research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Rusfertide: An injectable hepcidin mimetic being developed for the treatment of polycythemia vera (PV). The company has reported positive Phase 2 data. Competitors include therapies aimed at managing PV symptoms, such as phlebotomy and hydroxyurea, and other emerging therapies targeting similar mechanisms. The TAM for polycythemia vera is projected to reach billions of USD.
- PN-943: An oral alpha-4-beta-7 integrin specific antagonist being developed for inflammatory bowel disease (IBD). Competitors include biologics such as anti-TNF therapies and other oral small molecules. The IBD market is significantly larger than PV market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The demand for novel therapies continues to grow, particularly for chronic diseases.
Positioning
Protagonist Therapeutics is positioned as an innovative company focused on developing peptide-based therapeutics for unmet medical needs. Its competitive advantage lies in its peptide technology platform and expertise in developing targeted therapies.
Total Addressable Market (TAM)
The total addressable market for Protagonist's pipeline, addressing diseases like polycythemia vera (PV) and inflammatory bowel disease (IBD) is estimated to be several billion dollars. Protagonist is positioning itself within this large market with innovative peptide therapies.
Upturn SWOT Analysis
Strengths
- Innovative peptide technology platform
- Strong pipeline of drug candidates
- Experienced management team
- Positive clinical trial data for rusfertide
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- Relatively small company size compared to competitors
- Dependence on financing for research and development
Opportunities
- Potential for regulatory approval and commercialization of rusfertide
- Expansion of pipeline through new drug development
- Strategic partnerships with larger pharmaceutical companies
- Growing demand for targeted therapies
Threats
- Clinical trial failures
- Regulatory delays
- Competition from larger pharmaceutical companies
- Patent expirations
- Drug pricing pressure
Competitors and Market Share
Key Competitors
- INCY
- BMY
- MRK
Competitive Landscape
Protagonist Therapeutics faces competition from larger pharmaceutical companies with more resources. Its peptide technology offers a potential advantage, but clinical trial success is crucial.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth will be reflected in revenue and pipeline development reported in SEC filings.
Future Projections: Future projections depend on successful clinical trials, regulatory approvals, and commercialization. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing rusfertide through clinical trials and expanding its pipeline.
Summary
Protagonist Therapeutics is a biopharmaceutical company with an innovative peptide technology platform. The company's future hinges largely on the successful development and commercialization of rusfertide. Clinical trial success is critical, along with securing partnerships and funding. Competition from larger pharmaceutical companies and potential regulatory challenges pose ongoing risks.
Similar Companies
HALO
Halozyme Therapeutics Inc
HALO
Halozyme Therapeutics Inc
INCY
Incyte Corporation
INCY
Incyte Corporation
MRK
Merck & Company Inc
MRK
Merck & Company Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Protagonist Therapeutics Investor Relations
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is estimated and may not be precise. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 126 | Website https://www.protagonist-inc.com |
Full time employees 126 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.